News from NYU Langone Health
Same-day discharge after PCI for NSTE-ACS is on the rise
Cardiovascular Business
A study led by Sunil Rao, MD, director of interventional cardiology and the cardiac catheterization laboratory at NYU Langone Heart and a professor at NYU Grossman School of Medicine, shows a steady increase in same-day discharge for patients with non–ST-elevation acute coronary syndrome after percutaneous coronary intervention. Analyzing nearly 1.3 million records from the NCDR CathPCI Registry, the research found that while overall rates are low, the trend is rising, particularly since the COVID-19 pandemic. Dr. Rao noted significant variation by hospital and emphasized that while the practice appears safe for selected patients, overnight observation remains the standard of care.
1/12/2026
The issues orthopedic leaders say can't be ignored
Becker's Spine Review
Several orthopedic leaders identified urgent issues facing the specialty, including AI disruption, reimbursement pressures, and prior authorization delays. Joseph Zuckerman, MD, the Walter A. L. Thompson Professor of Orthopedic Surgery and chair of the Department of Orthopedic Surgery at NYU Langone Health, pointed to the increasing number of medical students applying to orthopedics. He noted that available residency positions are not keeping pace, resulting in more well-qualified students not matching each year. He suggested a more structured and strategic approach is needed to address this issue, considering the national demand for musculoskeletal care.
1/12/2026
Corriere Della Sera (Article is in Italian)
At NYU Langone Health, Robert A. Montgomery, MD, DPhil, chair of the Department of Surgery and director of the NYU Langone Transplant Institute, leads a pioneering xenotransplantation team, fostering a culture that, according to his colleague, prioritizes being "human" before being a scientist. A key member of this team is Massimo Mangiola, associate professor of Clinical Medicine and director of the Laboratory of Immunogenetics at the Transplant Institute at NYU Langone Health. Professor Mangiola's role is crucial: he assesses immunological risks, gives the final "green light" for transplant procedures, and monitors for rejection. He credits Dr. Montgomery with teaching him to always see the person and the life behind every lab result, a philosophy that guides their groundbreaking and successful work in overcoming organ rejection.
1/10/2026
Take Your Strength to the Next Level With These Advanced Workouts, Designed to Build Power and Speed
Runner's World
Runners can improve performance and prevent injury by deprioritizing running and focusing on strength training during their offseason, according to Heather A. Milton, MS, RCEP, CSCS, senior exercise physiologist supervisor at NYU Langone’s Sports Performance Center. Milton advises that switching the main focus to strength training can lead to appreciable gains and adaptations. She recommends lifting heavier weights for fewer repetitions, around six to eight, to improve lean mass quality and build a pillar of strength and stability. This approach also helps boost running economy, efficiency, and biomechanics for when the running cycle resumes.
1/12/2026
This Trendy Morning Habit Can Help You Feel More Awake and Focused
SELF Magazine
A TikTok trend involving jumping 50 times each morning is gaining attention for its potential health benefits, including improved focus and mood. Experts note the activity increases heart rate and blood flow. Thea Gallagher, PsyD, clinical associate professor and director of Wellness Programs in the Department of Psychiatry at NYU Langone Health, suggests that jumping can evoke feelings of joy and exuberance. “It also probably reminds you of when you were a kid and did a lot of jumping around.” When you jump, it can start a chain reaction in your mind that sparks those happy feelings, she explains.
1/12/2026
Are GLP-1s Actually A Mental Health Drug? New Findings On Mood, Cravings, and Mental Health
Women's Health
GLP-1 medications are showing unexpected benefits for mental health, with patients reporting reduced 'food noise,' cravings, and symptoms of depression and anxiety. The drugs, originally for diabetes and obesity, may also help treat addiction and other compulsive behaviors. Experts are studying how these medications interact with the brain's reward circuits. Holly F. Lofton, MD, director of the Medical Weight Management Program at NYU Langone Health, explains that the drugs mimic natural gut hormones that regulate appetite, and the medications amplify this effect. Clinical trials are underway to explore further applications for mental health conditions.
1/12/2026
Staying One Step Ahead of Infections With IgA Nephropathy
HealthCentral
People with IgA nephropathy (IgAN), a rare kidney disease, experience approximately twice the rate of infections compared to the general population, which can worsen symptoms. Joseph Lee, MD, transplant nephrologist at the NYU Langone Transplant Institute, notes that several common IgAN treatments suppress the immune system, increasing infection risk. Dr. Lee advises that patients can stay healthy by drinking clean water, ensuring sanitary food preparation, and following CDC vaccination guidelines, including for MMR, Tdap, flu, and COVID-19.
1/12/2026
CDC confirms norovirus outbreak that sickens nearly 90 people on Holland America cruise ship
Fox News
The CDC confirmed a norovirus outbreak aboard a Holland America cruise ship that sickened 81 passengers and eight crew members. Scott A. Weisenberg, MD, medical director of the NYU Langone Infectious Disease Associates and the NYU Travel Medicine Program, commented that the virus is highly contagious and can spread quickly in crowded settings. He advised that people with acute vomiting should avoid public areas, as the virus can spread through the air, and noted that proper hygiene is crucial for preventing transmission.
Also reporting was: New York Post, WITI-TV (Milwaukee, WI)
1/12/2026
What an Expert Wants You To Know Before Starting a GLP-1
Katie Couric Media
In an expert commentary piece, Melanie Jay, MD, associate professor of medicine at NYU Grossman School of Medicine and director of the NYU Langone Comprehensive Program on Obesity, discusses what patients should know before starting GLP-1 medications for weight loss. She highlights the excitement around these drugs but also warns of a 'dark side,' including the sale of unapproved and compounded versions online. Dr. Jay emphasizes that these are long-term medications for the chronic disease of obesity, not cosmetic tools, and require proper medical oversight to ensure safety and efficacy. She advises patients to get the right medication from a reputable source.
1/12/2026
Tukysa May Be ‘Patient Friendly’ Frontline Maintenance Option in HER2+ Breast Cancer
CURE Magazine
In an interview with Joshua K. Sabari, MD, assistant professor in the Department of Medicine at NYU Grossman School of Medicine and director of High Reliability Organization Initiatives at NYU Langone’s Perlmutter Cancer Center, an expert discussed the HER2CLIMB-05 clinical trial. The study evaluated Tukysa (tucatinib) as a first-line maintenance treatment for patients with HER2-positive breast cancer. Findings presented at the 2025 San Antonio Breast Cancer Symposium showed that adding Tukysa improved progression-free survival by nearly nine months. This may offer a new, patient-friendly targeted therapy option, allowing patients to avoid cytotoxic chemotherapy in the first-line setting.
1/12/2026
Addition of Lurbinectedin Improves Duration of Maintenance in ES-SCLC
Targeted Oncology
Joshua K. Sabari, MD, assistant professor in the Department of Medicine at NYU Grossman School of Medicine and director of High Reliability Organization Initiatives at NYU Langone’s Perlmutter Cancer Center, discussed the phase 3 IMforte trial, which demonstrated the benefit of adding lurbinectedin to maintenance immunotherapy for extensive-stage small cell lung cancer. He noted that the combination therapy showed a benefit across all patient subgroups, regardless of disease burden. Dr. Sabari highlighted the durability of response and improved disease control rates compared to atezolizumab alone. He also pointed out that the safety profile, primarily hematologic toxicity, is manageable and that patients on the combination therapy remained on treatment longer.
1/12/2026
Tempus, NYU Langone Health launch multi-year cancer research collaboration
Becker's Hospital Review
Tempus and NYU Langone Health have formed a multi-year strategic collaboration to advance cancer research through molecular profiling and data-driven insights. The partnership will support NYU Langone Health’s Center for Molecular Oncology at the Laura and Isaac Perlmutter Cancer Center, an initiative focused on understanding disease biology. Researchers aim to enhance genomic diagnostics to improve patient outcomes and accelerate the development of new diagnostic tools. The organizations are launching a prospective observational study involving patient sequencing. The collaboration also includes plans for research in biomarker discovery and AI-powered predictive algorithms.
1/12/2026
NYU Langone celebrates a decade since Lutheran Hospital merger in Brooklyn
HealthLeaders
NYU Langone Health celebrated the 10-year anniversary of its merger with the former Lutheran Medical Center in Sunset Park, Brooklyn. Hospital leadership highlighted significant improvements in quality, safety, and access to specialty care for local residents. As a result of these efforts, NYU Langone Hospital—Brooklyn now ranks among the lowest in mortality rates both in Brooklyn and nationally. This achievement is notable as the hospital serves one of the largest Medicaid populations in the United States, reinforcing its commitment to providing high-quality care close to home for the community.
1/12/2026
